Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
